= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
MSACL 2019 US : Saitman

MSACL 2019 US Abstract

Self-Classified Topic Area(s): Data Science

Clinical Mass Spectrometry Workflow Improvements by Transitioning from Manual to Auto-Data Review

Alec Saitman (1), Alicia Wright (1), Laura Gilbert (1), Mark Shearer (2).
(1) Providence Regional Laboratories, Portland, OR (2) Data Innovations, Burlington VT.


Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
 Alec Saitman (Presenter)
Providence Health and Services

Presenter Bio: Dr. Saitman received his Ph.D. in Organic Chemistry at the University of California, San Diego where he focused his research on the total synthesis of marine natural products. He completed his fellowship training in Clinical Chemistry and Toxicology in the Department of Pathology at the University of California, San Diego under the guidance of Dr. Robert Fitzgerald. Dr. Saitman is double boarded by the American Board of Clinical Chemistry in clinical chemistry and clinical toxicology. He is currently the director of clinical toxicology and special chemistry at Providence Regional Laboratories in Portland Oregon.

Relevant Financial Disclosures (within past 24 months)
Committee/Board/Advisory Board Policy and External Affairs Core Committee (PEACC) AACC

Abstract

A significant bottle-neck for clinical mass spectrometry laboratories is the data review component. Auto-data review processes decrease these bottlenecks by providing major improvements in quality and patient safety while simultaneously decreasing time to review the mass spectrometry data. This presentation provides insight into an auto-data review program developed by Providence Regional Laboratories in partnership the middleware company, Data Innovations. The program has unique advantage of providing dynamic rule flags against patient samples using calibrator averages of important data elements. By incorporating clinical mass spectrometry data review into middleware, we bridge the gap between mass spectrometry and automated instrumentation platforms.